ProShares Ultra Health Care ETF
RXL----
Pfizer reports Phase II data for 25vPnC infant vaccine candidate
WorldPharmaceuticals·- Pfizer reported Phase II trial data for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. - The trial demonstrated that a four-dose regimen elicited immune responses across all 25 serotypes with a safety profile comparable to PREVNAR 20. - These findings support Pfizer’s ongoing paediatric Phase III programme launched in 2026 to evaluate the vaccine in children.Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting | PFE Stock News
StockTitan·- The U.S. FDA has expanded the approval of Pfizer’s TALZENNA in combination with XTANDI for treating men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer carrying homologous recombination repair gene mutations. - The approval is supported by the Phase 3 TALAPRO-3 study, which demonstrated a 52% reduction in the risk of radiographic progression or death compared to placebo plus XTANDI. - This milestone makes the combination therapy available at an earlier stage of the disease to help delay progression for patients with HRR gene mutations.What Pfizer Holders Bought Into
Simplywall·- Pfizer investors faced a choice between a bull narrative valuing the stock at US$ 37.92 based on margin expansion and a bear case valuing it at US$ 23.58 due to patent cliffs. - Recent evidence cut both ways as higher revenue guidance supported demand assumptions, while quarterly losses left profit margin goals unproven. - Pfizer currently trades at US$ 30.03, requiring successful execution in new drug pipelines to offset pricing pressures and patent expirations.